Uncategorized Archives - Sangamo

Uncategorized

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

September 4th, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

August 7th, 2025

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

June 24th, 2025

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12th, 2025

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12th, 2025

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

May 6th, 2025

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

April 28th, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

April 3rd, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

March 17th, 2025

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

February 6th, 2025